Literature DB >> 14557749

NOD/LtSz-Rag1nullPfpnull mice: a new model system with increased levels of human peripheral leukocyte and hematopoietic stem-cell engraftment.

Leonard D Shultz1, Scott Banuelos, Bonnie Lyons, Rebecca Samuels, Lisa Burzenski, Bruce Gott, Pamela Lang, Jean Leif, Michael Appel, Aldo Rossini, Dale L Greiner.   

Abstract

BACKGROUND: A critical need exists for effective small-animal models that accept engraftment of human hematopoietic progenitor cells and mature lymphocytes. The purpose of this study was to determine the phenotypic effects of perforin (Pfp) deficiency on nonobese diabetic (NOD)-Rag1null mice and to evaluate the ability of NOD/LtSz-Rag1nullPfpnull recipients to support engraftment with human hematolymphoid cells.
METHODS: A new genetic stock of NOD mice doubly homozygous for targeted mutations at the recombination activating gene (Rag)-1 and Pfp genes was developed. NOD/LtSz-Rag1nullPfpnull mice were studied for immunopathologic and hematologic abnormalities. The ability of these mice to support engraftment with human peripheral blood mononuclear cells (PBMC) and umbilical-cord blood hematopoietic progenitor cells was assessed.
RESULTS: NOD/LtSz-Rag1nullPfpnull mice lacked mature B cells, T cells, natural killer (NK) cell cytotoxic activity and were devoid of serum immunoglobulin (Ig) throughout a 37-week lifespan. These mice supported heightened engraftment with human PBMC as compared with NOD/LtSz-Rag1null controls as evidenced by a 4- to 5-fold increase in percentages of human lymphocytes and a 7- to 13-fold increase in percentages of CD4+ T cells in the peripheral blood and spleen. Total numbers of human CD4+ T cells were increased approximately 20-fold in the spleens of NOD/LtSz-Rag1nullPfpnull mice. These mice also showed approximately 12-fold higher levels of engraftment with human umbilical-cord blood cells compared with NOD/LtSz-Rag1null mice.
CONCLUSIONS: NOD/LtSz-Rag1nullPfpnull mice are devoid of mature B cell, T cell, and NK cell cytotoxic activity, engraft at high levels with human PBMC, and hematopoietic progenitor cells and provide a new NK cell-deficient model for human hematolymphoid cell engraftment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557749     DOI: 10.1097/01.TP.0000083041.44829.2C

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  21 in total

1.  Membrane-bound human SCF/KL promotes in vivo human hematopoietic engraftment and myeloid differentiation.

Authors:  Shinsuke Takagi; Yoriko Saito; Atsushi Hijikata; Satoshi Tanaka; Takashi Watanabe; Takanori Hasegawa; Shinobu Mochizuki; Jun Kunisawa; Hiroshi Kiyono; Haruhiko Koseki; Osamu Ohara; Takashi Saito; Shuichi Taniguchi; Leonard D Shultz; Fumihiko Ishikawa
Journal:  Blood       Date:  2012-01-25       Impact factor: 22.113

Review 2.  Advancing animal models of human type 1 diabetes by engraftment of functional human tissues in immunodeficient mice.

Authors:  Michael A Brehm; Alvin C Powers; Leonard D Shultz; Dale L Greiner
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

3.  Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response.

Authors:  Aditya Barve; Lavona Casson; Maxwell Krem; Mark Wunderlich; James C Mulloy; Levi J Beverly
Journal:  Exp Hematol       Date:  2018-08-17       Impact factor: 3.084

4.  Targeted Molecular Radiotherapy of Pediatric Solid Tumors Using a Radioiodinated Alkyl-Phospholipid Ether Analog.

Authors:  Dana C Baiu; Ian R Marsh; Alexander E Boruch; Ankita Shahi; Saswati Bhattacharya; Justin J Jeffery; Qianqian Zhao; Lance T Hall; Jamey P Weichert; Bryan P Bednarz; Mario Otto
Journal:  J Nucl Med       Date:  2017-07-26       Impact factor: 10.057

Review 5.  Current advances in humanized mouse models.

Authors:  Ryoji Ito; Takeshi Takahashi; Ikumi Katano; Mamoru Ito
Journal:  Cell Mol Immunol       Date:  2012-02-13       Impact factor: 11.530

6.  A new immunodeficient hyperglycaemic mouse model based on the Ins2Akita mutation for analyses of human islet and beta stem and progenitor cell function.

Authors:  T Pearson; L D Shultz; J Lief; L Burzenski; B Gott; T Chase; O Foreman; A A Rossini; R Bottino; M Trucco; D L Greiner
Journal:  Diabetologia       Date:  2008-06-19       Impact factor: 10.122

7.  Human immune system development and rejection of human islet allografts in spontaneously diabetic NOD-Rag1null IL2rgammanull Ins2Akita mice.

Authors:  Michael A Brehm; Rita Bortell; Philip Diiorio; Jean Leif; Joseph Laning; Amy Cuthbert; Chaoxing Yang; Mary Herlihy; Lisa Burzenski; Bruce Gott; Oded Foreman; Alvin C Powers; Dale L Greiner; Leonard D Shultz
Journal:  Diabetes       Date:  2010-06-22       Impact factor: 9.461

8.  Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation.

Authors:  Michael A Brehm; Amy Cuthbert; Chaoxing Yang; David M Miller; Philip DiIorio; Joseph Laning; Lisa Burzenski; Bruce Gott; Oded Foreman; Anoop Kavirayani; Mary Herlihy; Aldo A Rossini; Leonard D Shultz; Dale L Greiner
Journal:  Clin Immunol       Date:  2010-01-21       Impact factor: 3.969

9.  Diabetes-related impairment in bone strength is established early in the life course.

Authors:  Krista Casazza; Lynae J Hanks; Gregory A Clines; Hubert M Tse; Alan W Eberhardt
Journal:  World J Diabetes       Date:  2013-08-15

10.  Expanded CD34+ human umbilical cord blood cells generate multiple lymphohematopoietic lineages in NOD-scid IL2rgamma(null) mice.

Authors:  Lisa J Giassi; Todd Pearson; Leonard D Shultz; Joseph Laning; Kristin Biber; Morey Kraus; Bruce A Woda; Madelyn R Schmidt; Robert T Woodland; Aldo A Rossini; Dale L Greiner
Journal:  Exp Biol Med (Maywood)       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.